$BSX · Curator's Audit · 5 October 2026
Thesis Strength: Neutral · confidence: low. Boston Scientific still throws off real cash and looks cheap if its two troubled franchises stop shrinking, but I can't yet say what the market has wrong. Confidence is low because a cyberattack has withdrawn guidance and an $11 billion cash deal is about to land, and the 28 October update quantifying both would raise it.
THE CASE
Boston Scientific makes minimally invasive devices, from heart-rhythm ablation to stents and urology. Two products drove the boom and now the bust. WATCHMAN, which seals off part of the heart to cut stroke risk, grew only 4% in the second quarter after about 30% last year, as new clinical evidence thinned referrals for standalone procedures. Farapulse, its ablation system, is losing share to rivals faster than management expected. Guidance was cut in April and again in July. The rest of the business, about three-quarters of sales, is still growing around 6%.
What the pitch leaves out. On 25 August hackers disrupted manufacturing, ordering and shipping. Operations are largely back, but in early September the company said it was unlikely to meet the July guidance and would update on 28 October. So the pitch's catalyst is now a quarter with a known hole in it. It also skips the pending $14.5 billion Penumbra deal, about $11 billion of it cash, funded largely with new debt, on top of $12.6 billion of existing debt and $539 million of cash.
The numbers. At $42.60 the company is worth about $62 billion. Free cash flow was $3.7 billion last year, with about $3.8 billion expected this year before the attack. By my estimate, interest on the deal debt trims that to roughly $3.5 billion, about $2.40 a share, a 5.6% yield. Adjusted earnings were guided to $3.28–3.32 a share before the attack, and management expects limited growth in 2027, so call it $3.25: about 13 times.
By my estimate, if growth picks up in 2028 and earnings reach about $3.75, 20 times gives $75, about 76% higher. If WATCHMAN and ablation keep shrinking and earnings stall near $3.10 at 11 times, that's $34, about 20% lower. Analysts average about $62.
How I tried to break it. The second quarter beat its own guidance at 7.5% growth, and the stock still slipped; the CEO then bought about $10 million of shares at $48.34. The market is pricing whether WATCHMAN's evidence shift and the ablation share losses are permanent, now with more debt and a damaged quarter on top.
The three tests.
- Is the downside limited by something real? About $3.5 billion a year of cash in a bad year is a real floor, but debt heading toward $23 billion (my estimate) leaves no balance-sheet cushion. Qualified yes.
- Is the upside meaningfully larger, with a way to get there? About 76% up against 20% down on my numbers, but the recovery depends on new products landing in 2028. Qualified yes.
- Is there a reason the market has it wrong? It fell on a beat, and I can't yet show the losses are temporary. No.
What you'd be betting on. That the steady three-quarters of the business keeps compounding while WATCHMAN and ablation find a floor.
My call. Neutral. The case against: share losses to well-funded rivals, $11 billion of new debt and a cyberattack all land on a management that has missed its own forecasts twice. The better thesis than the pitch's: not a snap-back on one report, but a cash-generating device maker priced like a fading one.
Where it becomes interesting. Below about $30, the post-deal cash yield is near 8% (my estimate) and my downside case is in the price.
WHAT WOULD CHANGE MY VIEW
28 October: an outlook that sizes the cyber hit as one-off, keeps the rest of the business near 6% organic growth, and holds 2027 earnings near $3.25 supports it. A wider hit or a lower 2027 makes it Weak.
Penumbra's close, expected in the second half: financing terms that keep debt near three times cash earnings support it; buybacks paused for years weaken it.
Early 2027 results: WATCHMAN standalone procedures stabilising would clear the third test.
This is my personal opinion, not investment advice.
